Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 8;11(3):469.
doi: 10.3390/diagnostics11030469.

Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment

Eisuke Iwasaki  1 , Seiichiro Fukuhara  2 , Masayasu Horibe  1 , Shintaro Kawasaki  1 , Takashi Seino  1 , Yoichi Takimoto  1 , Hiroki Tamagawa  1 , Yujiro Machida  1 , Atsuto Kayashima  1 , Marin Noda  1 , Hideyuki Hayashi  3 , Takanori Kanai  1
Affiliations
Review

Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment

Eisuke Iwasaki et al. Diagnostics (Basel). .

Abstract

Pancreatic cancer is the most lethal solid malignancy, and the number of patients with pancreatic cancer is increasing. Systemic chemotherapies are often ineffective for such patients, and there is an urgent need for personalized medicine. Unlike other types of cancer, personalized treatments for pancreatic cancer are still in development. Consequently, pancreatic cancer is less sensitive to anticancer drugs and is often refractory to common treatments. Therefore, advances in personalized medicine for pancreatic cancer are necessary. This review examined advances in personalized medicine for pancreatic cancer, including the use of endoscopic ultrasound (EUS)-guided sampling. EUS-guided sampling is widely used for diagnosing pancreatic tumors and is expected to be applied to sampled tissues. Additionally, there has been an increase in clinical research using EUS-guided sampling. The combination of precision medicine using genomic testing and pharmacological profiles based on high-throughput drug sensitivity testing using patient-derived organoids is expected to revolutionize pancreatic cancer treatment.

Keywords: EUS-guided sampling; pancreatic cancer; patient-derived organoid; precision medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet. 2011;378:607–620. doi: 10.1016/S0140-6736(10)62307-0. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Pishvaian M.J., Blais E.M., Brody J.R., Lyons E., DeArbeloa P., Hendifar A., Mikhail S., Chung V., Sahai V., Sohal D.P.S., et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020;21:508–518. doi: 10.1016/S1470-2045(20)30074-7. - DOI - PMC - PubMed
    1. Li D.F., Wang J.Y., Yang M.F., Xiong F., Zhang D.G., Xu Z.L., Luo M.H., Jing Z.D., Wang K.X., Wang L.S., et al. Factors associated with diagnostic accuracy, technical success and adverse events of endoscopic ultrasound-guided fine-needle biopsy: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2020;35:1264–1276. doi: 10.1111/jgh.14999. - DOI - PubMed

Grants and funding

LinkOut - more resources